Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699995 · ClinicalTrials.gov registry record · NA
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
A NA study of Cutaneous Melanoma and Skin Carcinoma, sponsored by OHSU Knight Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03699995: Active NA study of Cutaneous Melanoma and Skin Carcinoma, sponsored by OHSU Knight Cancer Institute.
NCT03699995 is a NA study of Cutaneous Melanoma and Skin Carcinoma that is active but no longer recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 100 participants, below the 364-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03699995, a NA study of Cutaneous Melanoma and Skin Carcinoma, is active but no longer recruiting, sponsored by OHSU Knight Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.
Primary Outcome
Sensitivity is defined as recommend immediate biopsy (red) lesions correctly identified as red by the dermatologists. The nature of statistical data analyses will be descriptive and exploratory to estimate effect sizes and their variation as well as generate hypotheses for the future study design. Sensitivity and specificity will be estimated along with exact 95% confidence intervals.
Conditions Studied
Interventions
- PROCEDURE Imaging Procedure
- DRUG Lidocaine
- PROCEDURE Punch Biopsy
- OTHER Confocal Microscopy
- OTHER Dermoscopy
Study Locations (1)
Oregon
- Sancy Leachman - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-05-18 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT03699995 still lists
NCT03699995 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 364-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (73% lower).
The record links to 3 conditions, with Cutaneous Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Imaging Procedure is the first listed.
NCT03699995 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03699995 about?
NCT03699995 is a clinical study titled "MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma". This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.
What is the current status of trial NCT03699995?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2018-05-18. Estimated completion is 2026-12-31.
What conditions does trial NCT03699995 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Skin Carcinoma, Melanocytic Nevus.
What interventions are being tested in trial NCT03699995?
The interventions under investigation include: Imaging Procedure (PROCEDURE), Lidocaine (DRUG), Punch Biopsy (PROCEDURE), Confocal Microscopy (OTHER), Dermoscopy (OTHER).
Who is sponsoring clinical trial NCT03699995?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03699995 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03699995's enrollment target sits among peer trials
100 16th of 30 higher than 14 of 30 other Cutaneous Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
RECRUITING · NA
-
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
ACTengine® IMA203 Combined With mRNA-4203
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI